Visudyne
information and resources from the National Cancer Institute
NCI Thesaurus | Visudyne
(Other name for: benzoporphyrin derivative monoacid ring A)NCI Thesaurus | Visudyne
(Other name for: benzoporphyrin derivative monoacid ring A)
|
|
|
|
news articles
Half a billion in cash, but what to do with it? Mar 25, 2006
Globe and Mail, ...approval in 2000, a debate was raging in its Vancouver offices about how to spend the revenue windfall from its new highly successful Visudyne anti-blindness ...
NSERC: UBC Professor and Lead Creator of Key Ophthalmic Drug Wins ... Mar 20, 2006
CCNMatthews (press release), The creator of Visudyne TM , one of the world's most successful ophthalmic products, is the winner of the 2005 Gerhard Herzberg Canada Gold Medal for Science ...
People on the move: Bob Butchofsky Mar 12, 2006
El Paso Times, He joined QLT Inc. in 1998 and has played an integral role in the successful launch and commercialization of QLT's lead drug, Visudyne. ...
Genentech Granted Six-Month Priority Review for Lucentis for the ... Feb 28, 2006
International News Service, In addition, Lucentis is the first investigational therapy to have demonstrated a clinical benefit compared to verteporfin (Visudyne(R)) photodynamic therapy ...
Regular eye exams may save your vision Mar 5, 2006
Barre Montpelier Times Argus, Several drugs, Visudyne by QLT and Novartis and Macugen by Eyetech Pharmaceuticals and Pfizer, have also been shown to slow deterioration of eyesight in wet ...
Wanted: bucks for Canadian biotech Mar 23, 2006
Canadian Business, QLT was obviously the leader, with half a billion [in sales] from Visudyne, and there's TLC too, if you think about laser eye surgery. ...
QLT Updates on the US Eligard(R) Patent Litigation Mar 6, 2006
CNW Telbec (Communiqués de presse), ...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R ...
Othera Pharmaceuticals Appoints Al Reaves as Senior Vice President ... Mar 22, 2006
PharmaLive.com (press release), During his career, he has been responsible for bringing numerous ophthalmic products to market, and previously, led the Visudyne global clinical development ...
QLT's Board of Directors Appoints Robert Butchofsky as CEO Feb 27, 2006
Canada NewsWire (press release), ...in 1998, he has played an integral role in the successful launch and commercialization of QLT's lead drug, Visudyne(R). He was appointed Vice President ...
Lucentis Gets Priority Review Mar 1, 2006
TheStreet.com Another trial found Lucentis to be more effective than Visudyne, a treatment from QLT (QLTI:Nasdaq - commentary - research - Cramer's Take) and Novartis (NVS ...
Silver miner names Goldcorp exec CEO Mar 16, 2006
Business Edge, Shares of Vancouver-based QLT have been under pressure for months amid positive test results of a rival drug to its key drug Visudyne, and difficulty in ...
Finalists for Canada's top science prize named Mar 6, 2006
Laboratory Products News, His groundbreaking achievement is the creation of the porphyrin-based drug Visudyne - the world's first treatment for age-related macular degeneration, the ...
QLT to appeal Feb 28, 2006
Globe and Mail, Shares of QLT have been under pressure for months amid positive test results of a rival drug to Visudyne and difficulty in following up its initial success ...
UPDATE 1-QLT cuts Visudyne forecast, announces job cuts Dec 7, 2005
Reuters Research) (QLTI.O: Quote, Profile, Research) on Thursday cut its sales forecast for its main revenue earner, anti-blindness treatment Visudyne, and announced a ...
QLT Trims Revenue Forecast for Visudyne, Will Slash Costs Dec 8, 2005
Bloomberg ...the Canadian maker of eye, skin and urology drugs, plans to cut jobs, sell some businesses and focus on eye care to reduce costs as its Visudyne eye treatment ...
QLT Inc. cuts staff by 46% in restructuring, reduces Visudyne ... Dec 8, 2005
CBC News, ...is cutting its workforce by 46 per cent and reducing its sales forecast for key eye drug Visudyne, a treatment for macular degeneration. ...
QLT slashing staff as Visudyne sales hopes fade, Eligard limps Dec 8, 2005
CBC News, QLT Inc. is cutting its workforce by as much as 46 per cent and reducing its sales expectations for key eye drug Visudyne. The moves ...
QLT slashes Visudyne forecast Dec 8, 2005
Reuters Canada, OTTAWA (Reuters) - QLT Inc. (QLT.TO: Quote) (QLTI.O: Quote) slashed its sales forecast for its main product, anti-blindness treatment Visudyne, on Thursday and ...
QLT slashing staff as Visudyne sales hopes fade, Eligard limps Dec 8, 2005
CBC News, ...hit their lowest point in nearly a decade on Thursday after the company lowered its sales expectations for its marquee eye drug Visudyne and said it will slash ...
QLT cuts Visudyne forecast, announces job cuts Dec 8, 2005
Reuters Canada, ...(QLT.TO: Quote) (QLTI.O: Quote) on Thursday cut its sales forecast for its main revenue earner, anti-blindness treatment Visudyne, and announced a ...
QLT slashes Visudyne forecast Dec 8, 2005
Metro Toronto, ...slashed its sales forecast for its main product, anti-blindness treatment Visudyne, on Thursday and said it would cut staff by up to 46 percent as it deals ...
QLT slashing staff as Visudyne sales hopes fade, Eligard limps Dec 8, 2005
Canadian Business, ...hit their lowest point in nearly a decade on Thursday after the company lowered its sales expectations for its marquee eye drug Visudyne and slashed its ...
QLT cuts Visudyne forecast, announces job cuts Dec 8, 2005
Metro Toronto, ...on Thursday cut its sales forecast for its main revenue earner, anti-blindness treatment Visudyne, and announced a restructuring program that includes cuts to ...
QLT announces repositioning and streamlining for future growth Dec 7, 2005
PR Newswire (press release), ..."One of the near-term hurdles is the impact of competition on our lead product Visudyne(R). While we expect Visudyne to remain a key treatment option for ...
QLT takes some unpleasant medicine Dec 9, 2005
Vancouver Sun (subscription), 1 as the company slashed spending in the face of declining sales forecasts and increased competition for its lead product, the anti blindness treatment Visudyne ...
QLT announces repositioning and streamlining for future growth Dec 7, 2005
Yahoo! News (press release) ..."One of the near-term hurdles is the impact of competition on our lead product Visudyne®. While we expect Visudyne to remain a ...
International Approvals: Retaane, Avelox, Generic Zinnat Dec 19, 2005
Medscape (subscription) In addition, results of a phase 3 clinical study comparing anecortave acetate and photodynamic therapy using verteporfin (Visudyne, made by Novartis AG ...
Under pressure, QLT restructures Dec 8, 2005
Globe and Mail, But the company doesn't have a great track record of expanding beyond its flagship blindness drug Visudyne, which was launched five years ago. ...
QLT Boosts Buyback Plan to $100 Million Dec 13, 2005
MSN Money ...of Dec. 8. The company's Visudyne product fights a type of age-related macular degeneration, a cause of blindness. Shares of QLT ...
QLT cutting staff amid pressure on eye drug sales Dec 8, 2005
CBC British Columbia (Audio), ...says increasing competition for its Visudyne macular degeneration drug in the US is forcing it to cut almost half of its staff and trim its sales outlook for ...
Updates, advisories and surprises Dec 8, 2005
Investor's Business Daily (subscription) QLT tumbles on lower Visudyne view, restructuring plans (12:17 PM ET) NEW YORK (MarketWatch) -- Shares of QLT Inc.(QLTI)fell almost 9% to $6.35 after the ...
Health Stocks in Motion Dec 8, 2005
TheStreet.com ...the worst-performing health-related stocks Thursday, dropping 11% after the biopharmaceutical company cut its sales forecast for its Visudyne eye treatment and ...
QLT to cut jobs in face of competition Dec 8, 2005
Rocky Mountain News, ...with analysts. He blamed increasing competition for Visudyne, which treats age-related macular degeneration, an eye disease. Shares ...
QLT to host conference call to discuss strategic update Dec 5, 2005
PR Newswire (press release), ...and manufacture of innovative drug therapies with our unique technology platforms to create highly successful products such as Visudyne(R) and Eligard(R). For ...
QLT upgraded to "hold" Dec 12, 2005
New Ratings QLT has announced a restructuring initiative, while reducing the sales guidance for its Visudyne segment for 2005 to $480 million-$485 million from the earlier ...
QLT announces TSX approval to increase its share repurchase ... Dec 13, 2005
CNW Telbec (Communiqués de presse), ...of innovative drug therapies with our two unique technology platforms, photodynamic therapy and Atrigel(R), to create products such as Visudyne(R) and Eligard(R ...
Canadian Stocks Rise for Sixth Day, Led by Energy Companies Dec 8, 2005
Bloomberg The Vancouver-based drugmaker plans to cut jobs, sell some businesses and focus on eye care to reduce costs as its Visudyne eye treatment brings in less ...
Canadian Stocks Rise for Sixth Day; Energy Shares, Nexen Gain Dec 8, 2005
Bloomberg ...in the S&P/TSX The Vancouver-based drugmaker plans to cut jobs, sell some businesses and focus on eye care to reduce costs as its Visudyne eye treatment brings ...
US jury hands QLT a setback in lengthy drug patent battle Dec 15, 2005
Vancouver Sun (subscription), Last week, QLT announced it would be laying off more than 100 employees in the face of declining sales forecasts and increased competition for Visudyne. ...
Highlights of rising and falling US stocks Dec 8, 2005
Investor's Business Daily (subscription) QLT Inc. (QLTI) announced a restructuring plan and lowered its 2005 outlook for sales of Visudyne, a treatment for wet age-related macular degeneration, to a ...
Highlights of rising and falling US stocks Dec 8, 2005
Investor's Business Daily (subscription) QLT Inc. (QLTI) shed 11% after it announced a restructuring plan and lowered its 2005 outlook for sales of Visudyne, a treatment for wet age-related macular ...
QLT to sell local site Dec 9, 2005
The Coloradoan, After several quarters of fierce competition and mediocre response to Visudyne, the company's signature drug used to treat blindness, QLT also announced its ...
Clinical Trials Update: Nov. 21, 2005 Nov 21, 2005
Austin American-Statesman (subscription), The purpose of this research study is to compare the safety and effectiveness of three different investigational combination therapies with Visudyne TM . ...
QLT Announces Partial Result in Eligard Patent Litigation Dec 15, 2005
ag-IP-news Agency, ...of innovative drug therapies with two unique technology platforms, photodynamic therapy and Atrigel, to create products such as Visudyne and Eligard.
Stock market signals mainly negative; crude oil price rises Dec 8, 2005
CBC News, ...of Vancouver said Thursday it is cutting its workforce by 46 per cent and reducing its sales forecast for key eye drug Visudyne, a treatment for macular ...
Big Movers in the Stock Market Dec 8, 2005
Washington Post, ...overseas growth. The Canadian drugmaker plans to cut 46 percent of its workers and lowered projected sales for eye treatment Visudyne.
Stocks seen climbing on resource shares Dec 8, 2005
Reuters Canada, Quote) could also see interest on Thursday after it said it cut its sales forecast for its main revenue earner, anti-blindness treatment Visudyne, and outlined ...
StreetNotes: A Daily Roundup of Street Research Dec 9, 2005
TheStreet.com Morgan Stanley: Morgan Stanley said it is lowering its rating on QLTI to Equalweight with a $7 target price on concerns surrounding Visudyne and management's ...
Love Your Losers Nov 21, 2005
Motley Fool One of biotech analyst Charly Travers' key investment theses for QLT was that its Visudyne product for age-related macular degeneration (AMD) would keep ...
iCo Therapeutics Announces Strategic Advisory Team Nov 30, 2005
PR Newswire (press release), Under Dr. Levy's stewardship QLT rose to become one the leading biotech companies worldwide with the launch of Visudyne in 2000 to treat age-related macular ...
|
|
